The latest market report published by Credence Research,
Inc. “Global Pharmacogenomics
Market - Growth, Share, Opportunities, Competitive Analysis, and
Forecast, 2016 - 2023,” the global pharmacogenomics market was valued
at US$ 7,167.6 Mn in 2015, and is expected to reach US$ 11,938.8 Mn by 2024,
expanding at a CAGR of 5.6% from 2016 to 2024.
Market Insights
Pharmacogenomics or personalized medicine is defined as “the
tailoring of medical treatment to the specific characteristics of each
patient.” This concept in reality involves the ability to classify individuals
into subpopulations that are uniquely or disproportionately susceptible to a
particular disease or responsive to a specific treatment. Personalized medicine
emphasizes on paradigm shift in medicine from reaction to prevention. The
individual response to the drug varies according to the genetic composition.
Most of the responses are positive and show improvement while few face the side
effects. To address those variations, it is necessary to study how the drug
processing is affected by the genes. So when the genetic variation is affecting
the drug processing and response, there is scope of the clinical study to be
conducted and based on the result, adjust the dosage or to find a different
drug according to the genetic composition of an individual.
Browse the full report Global Pharmacogenomics
Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016
– 2024 report at http://www.credenceresearch.com/report/pharmacogenomic-market
Genetic study of an individual helps in predicting the susceptibility
to disease, its progression and overall improves the diseases detection. Able
to design unique disease prevention strategies, prescribe more effective drugs
and reduce the ADR’s, enhance quality of life, increase patient compliance;
therefore able to optimize the health care cost by reducing the time, cost and
rate of failure of clinical trials. Personalized medicine incorporates strong
fundamental knowledge about the molecular and genetic frame, which is the main
driver for its proliferation.
The global pharmacogenomics market is segmented based on
technology type as microarray, sequencing, polymerase chain reaction and other
technologies. Sequencing dominates the market, especially with the advent of
next generation sequencing attributed by high throughput screening, high
accuracy and speed. Further elucidation of this market in terms of technologies
is as follows:
- Microarray
- Sequencing
- Sanger
Sequencing
- Pyrosequencing
- Next-Generation
Sequencing
- Polymerase
Chain Reaction
- Other
Technologies
- Mass
Spectrometry
- Electrophoresis
The global pharmacogenomics market is further segmented in
terms of therapeutic application such as oncology, cardiology, psychiatry,
infectious diseases, pain management, neurological disorders and others. Among
these, oncology segment dominates the therapeutic market followed by psychiatry
and infectious diseases.
Currently, North America occupies the largest revenue share
for global pharmacogenomics market, largely dominated by the U.S. Major growth
drivers of North America market are presence of extensive and evolved
healthcare infrastructure, increasing preference for better, cost effective and
personalized therapeutics for various diseases and infections. Asia Pacific is
expected to be the most attractive regional market and is anticipated to
witness extensive growth during the forecast period.
Market Competition Assessment:
Key players in the Pharmcogenomicsmarket are
Abbott Laboratories, Inc., Affymetrix, Inc., AstraZeneca
plc, Assurex Health, Bayer AG, GeneDX, F. Hoffmann-La Roche Ltd., Illumina,
Inc., Myriad Genetics, Inc., Merck & Co, GE Healthcare, GlaxoSmithKline,
Johnson & Johnson, Pfizer, Inc., Pathway Genomics, Qiagen, Inc., Teva
Pharmaceutical Industries Ltd, Thermo Fisher Scientific, Transgenomic, Inc.
Key Market Movements:
- Focus
on personalized medicine emphasizing on the paradigm shift in medicine
from reaction to prevention. Able to design unique disease prevention
strategies, prescribe more effective drugs and reduce the ADR’s, enhance
quality of life, increase patient compliance.
- Recently,
pharmacogenomics have being extensively used in drug development. It is
used at various stages of drug development assessing and identifying
effect of drug target polymorphisms on drug response.
- Discovery
of new biological mechanisms and identification of molecules with improved
efficacy and safety
Request Sample: http://www.credenceresearch.com/sample-request/58357
ToC:
1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.1. Report Scope and Description
1.2. Research Methodology
2. Executive Summary
2.1. Market Snapshot: Global Pharmacogenomics Market
2.2. Global Pharmacogenomics Market, by Technology, 2015 & 2024 (Value %)
2.3. Global Pharmacogenomics Market, by Application, 2015 & 2024 (Value %)
2.4. Global Pharmacogenomics Market, by Geography, 2015 (Value %)
2.1. Market Snapshot: Global Pharmacogenomics Market
2.2. Global Pharmacogenomics Market, by Technology, 2015 & 2024 (Value %)
2.3. Global Pharmacogenomics Market, by Application, 2015 & 2024 (Value %)
2.4. Global Pharmacogenomics Market, by Geography, 2015 (Value %)
3. Market Overview and Future Outlook
3.1. Global Pharmacogenomics Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rise in investment in research and development
3.3.1.2. Advancement in technology pharmacogenomics engineering to create in vivo environment
3.3.2. Challenge
3.3.2.1. Lack of consistency in pharmacogenomics products
3.3.3. Opportunities
3.3.3.1. Focus on regenerative medicine
3.3.3.2. Increased awareness of organ transplantation
3.4. Attractive Investment Proposition, 2015
3.5. Market Positioning Analysis of Key Players: Global Pharmacogenomics Market, 2015
3.1. Global Pharmacogenomics Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rise in investment in research and development
3.3.1.2. Advancement in technology pharmacogenomics engineering to create in vivo environment
3.3.2. Challenge
3.3.2.1. Lack of consistency in pharmacogenomics products
3.3.3. Opportunities
3.3.3.1. Focus on regenerative medicine
3.3.3.2. Increased awareness of organ transplantation
3.4. Attractive Investment Proposition, 2015
3.5. Market Positioning Analysis of Key Players: Global Pharmacogenomics Market, 2015
4. Global Pharmacogenomics Market, By Technology, 2014 – 2024
(US$)
4.1. Overview
4.2. Microarray
4.3. Sequencing
4.3.1. Sanger Sequencing
4.3.2. Pyrosequencing
4.3.3. Next-Generation Sequencing
4.4. Polymerase Chain Reaction
4.5. Other Technologies…
4.1. Overview
4.2. Microarray
4.3. Sequencing
4.3.1. Sanger Sequencing
4.3.2. Pyrosequencing
4.3.3. Next-Generation Sequencing
4.4. Polymerase Chain Reaction
4.5. Other Technologies…
Request For Customization: http://www.credenceresearch.com/request-for-customization/58357
About Us:
Credence Research is a worldwide market
research and counseling firm that serves driving organizations, governments,
non-legislative associations, and not-for-benefits. We offer our customers some
assistance with making enduring enhancements to their execution and understand
their most imperative objectives. Over almost a century, we’ve manufactured a
firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
No comments:
Post a Comment